Autores: Mantilla Mora Gerardo, Sierra Ariza Iván Darío, Mendivil Cárdenas Carlos Olimpo, Pérez Sánchez Clara Eugenia
High postprandial concentrations of chylomicrons and its remnants are correlated with an atherosclerosis progression. Apolipoprotein B-48 is an essential component of these lipoproteins and appears to be a suitable marker for clinical studies of postprandial lipid metabolism and its relationship to cardiovascular risk. A double-sandwich ELISA was developed for routine Apo B-48 quantification in untreated human plasma. The postprandial behavior of Apo B-48 in healthy young individuals was described employing the method, and correlations between plasma Apo B-48 and lipid and clinical parameters. A polyclonal antibody directed against the carboxy-terminal extreme of Apo B-48 was developed, and appropriate calibrators were prepared using an affinity column to which the developed antibody was attached. A mouse monoclonal antibody able to recognize both Apo B-48 and Apo B-100 was used as second antibody, and an enzyme coupled anti-mouse IgG was used as third antibody. The plasma Apo B-48 levels were determined in 42 healthy young individuals of both sexes in the fasting state and hourly after the consumption of a breakfast with 40 g fat. The technique showed an intra-assay variation of 3,0-3,8%. Plasma Apo B-48 fluctuated between 0,5 and 0,8 mg/L in the fasting state, with an hourly increase to reach a maximum between 4,6 and 8,4 mg/L at the third postprandial hour. The postprandial Apo B-48 area under curve and third hour Apo B-48 showed a strong correlation with body mass index (r=0,58 and 0,8 respectively). This paper presents a novel assay that makes Apo B-48 quantification easier and faster with adequate precision and without requirements for sample processing. Plasma Apo B-48 in healthy young individuals showed postprandial kinetics characterized by low fasting concentrations that increase to a peak about 3 hours after a meal and return to low values after 6 hours.
Palabras clave: Apo B-48 postprandial lipemia cardiovascular risk immunoassay chylomicrons lipoproteins.
2003-12-23 | 1,568 visitas | Evalua este artículo 0 valoraciones
Vol. 6 Núm.18. Diciembre 2003 Pags. 130-136 MedUNAB 2003; 6(18)